Formerly the senior VP of Science and Innovation at GlaxoSmithKline PLC, Perry Nisen brought both an experience-earned perspective and a set of goals when he took over as CEO of Sanford Burnham Prebys Medical Discovery Institute, mainly to help push the biopharmaceutical industry toward innovation and fresh thinking and away from a perceived focus on lower-risk business opportunities.
Tech Transfer Roundup: Academia's Role In De-Risking Novel Science
The Sanford Burnham Prebys institute is driving innovation in areas like neurodegenerative disease and immuno-oncology. Plus the latest tech transfer deals: two in cancer, one in asthma/allergies and another in lipid nanoparticle technology.
